Skip to main content
SpringerLink
Log in

Molecular Subtypes and Genomic Signatures of Hepatocellular Carcinoma for Prognostication and Therapeutic Decision-Making

  • Chapter
  • First Online:
Hepatocellular Carcinoma

Part of the book series: Molecular and Translational Medicine ((MOLEMED))

Abstract

Molecular classification of cancers has significantly improved patient outcomes through the implementation of treatment protocols tailored to the abnormalities present in each patient’s cancer cells. Important subtypes with characteristic molecular features as potential therapeutic targets are likely to exist for all tumor lineages, including hepatocellular carcinoma (HCC), but have yet to be discovered and validated as targets. Because each tumor accumulates hundreds or thousands of genomic and epigenetic alterations of critical genes, it is challenging to identify and validate candidate tumor aberrations as therapeutic targets or biomarkers that predict prognosis or response to therapy. Therefore, it is important to have good overview of our understanding on molecular and genomic subtypes of HCC. Systems-level integration of data from multiple studies and development of new technologies analyzing patient tissues hold great promise for the identification of novel therapeutic targets and linked predictive biomarkers, allowing implementation of personalized medicine for HCC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sander C. Genomic medicine and the future of health care. Science. 2000;287(5460):1977–8.

    CAS  PubMed  Google Scholar 

  2. Stenson PD, Mort M, Ball EV, Evans K, Hayden M, Heywood S, et al. The Human Gene Mutation Database: towards a comprehensive repository of inherited. Hum Genet. 2017;136(6):665–77.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Guttmacher AE, Collins FS. Realizing the promise of genomics in biomedical research. JAMA. 2005;294(11):1399–402.

    CAS  PubMed  Google Scholar 

  4. Tian Q, Price ND, Hood L. Systems cancer medicine: towards realization of predictive, preventive. J Intern Med. 2012;271(2):111–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Dienstmann R, Rodon J, Barretina J, Tabernero J. Genomic medicine frontier in human solid tumors: prospects and challenges. J Clin Oncol. 2013;31(15):1874–84.

    PubMed  Google Scholar 

  6. Macconaill LE, Garraway LA. Clinical implications of the cancer genome. J Clin Oncol. 2010;28(35):5219–28.

    PubMed  PubMed Central  Google Scholar 

  7. Mendelsohn J. Personalizing oncology: perspectives and prospects. J Clin Oncol. 2013;31(15):1904–11.

    CAS  PubMed  Google Scholar 

  8. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology. 2004;40(3):667–76. https://doi.org/10.1002/hep.20375.

    Article  CAS  PubMed  Google Scholar 

  9. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med. 2006;12(4):410–6. https://doi.org/10.1038/nm1377.

    Article  CAS  PubMed  Google Scholar 

  10. Calvet X, Bruix J, Gines P, Bru C, Sole M, Vilana R, Rodes J, et al. Prognostic factors of hepatocellular carcinoma in the west: a multivariate. Hepatology. 1990;12(4 Pt 1):753–60.

    CAS  PubMed  Google Scholar 

  11. Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C. A new prognostic classification for predicting survival in patients with. J Hepatol. 1999;31(1):133–41.

    CAS  PubMed  Google Scholar 

  12. Investigator C. A new prognostic system for hepatocellular carcinoma: a retrospective study of. Hepatology. 1998;28(3):751–5.

    Google Scholar 

  13. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, et al. Natural history of hepatocellular carcinoma and prognosis in relation to. Cancer. 1985;56(4):918–28.

    CAS  PubMed  Google Scholar 

  14. Tan CK, Law NM, Ng HS, Machin D. Simple clinical prognostic model for hepatocellular carcinoma in developing. J Clin Oncol. 2003;21(12):2294–8.

    PubMed  Google Scholar 

  15. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–50. https://doi.org/10.1002/hep.29913.

    Article  PubMed  Google Scholar 

  16. Kim CK, Lim J, Lee WJ, Lee WJ. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver. J Ultrasound Med. 2001;20(2):99–104.

    CAS  PubMed  Google Scholar 

  17. Lencioni R, Cioni D, Bartolozzi C. Tissue harmonic and contrast-specific imaging: back to gray scale in ultrasound. Eur Radiol. 2002;12(1):151–65.

    PubMed  Google Scholar 

  18. Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis. 2005;25(2):133–42.

    PubMed  Google Scholar 

  19. Leykum LK, El-Serag HB, Cornell J, Papadopoulos KP. Screening for hepatocellular carcinoma among veterans with hepatitis C on disease. Clin Gastroenterol Hepatol. 2007;5(4):508–12.

    PubMed  Google Scholar 

  20. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 2002;31(4):339–46. https://doi.org/10.1038/ng0802-339.

    Article  CAS  PubMed  Google Scholar 

  21. Marquardt JU, Andersen JB, Thorgeirsson SS. Functional and genetic deconstruction of the cellular origin in liver cancer. Nat Rev Cancer. 2015;15(11):653–67 LID. https://doi.org/10.1038/nrc4017.

    Article  CAS  PubMed  Google Scholar 

  22. Libbrecht MW, Noble WS. Machine learning applications in genetics and genomics. Nat Rev Genet. 2015;16(6):321–32. https://doi.org/10.1038/nrg3920.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245–55.

    PubMed  Google Scholar 

  24. Cheung ST, Chen X, Guan XY, Wong SY, Tai LS, Ng IO, So S, et al. Identify metastasis-associated genes in hepatocellular carcinoma through. Cancer Res. 2002;62(16):4711–21.

    CAS  PubMed  Google Scholar 

  25. Iizuka N, Oka M, Yamada-Okabe H, Nishida M, Maeda Y, Mori N, Takao T, et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of. Lancet. 2003;361(9361):923–9.

    CAS  PubMed  Google Scholar 

  26. Kurokawa Y, Matoba R, Takemasa I, Nagano H, Dono K, Nakamori S, Umeshita K, et al. Molecular-based prediction of early recurrence in hepatocellular carcinoma. J Hepatol. 2004;41(2):284–91.

    CAS  PubMed  Google Scholar 

  27. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using. Nat Med. 2003;9(4):416–23.

    CAS  PubMed  Google Scholar 

  28. Roessler S, Jia HL, Budhu A, Forgues M, Ye Q-H, Lee J-S, Thorgeirsson SS, et al. A unique metastasis gene signature enables prediction of tumor relapse in. Cancer Res. 2010;70(24):10202–12.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Woo HG, Park ES, Cheon JH, Kim JH, Lee J-S, Park BJ, Kim W, et al. Gene expression-based recurrence prediction of hepatitis B virus-related human. Clin Cancer Res. 2008;14(7):2056–64.

    CAS  PubMed  Google Scholar 

  30. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(10):698–711.

    PubMed  Google Scholar 

  31. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, et al. Predicting survival after liver transplantation in patients with hepatocellular. Lancet Oncol. 2009;10(1):35–43.

    PubMed  Google Scholar 

  32. Minguez B, Hoshida Y, Villanueva A, Toffanin S, Cabellos L, Thung S, Mandeli J, et al. Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol. 2011;55(6):1325–31.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Sagiv E, Memeo L, Karin A, Kazanov D, Jacob-Hirsch J, Mansukhani M, Rechavi G, et al. CD24 is a new oncogene, early at the multistep process of colorectal cancer. Gastroenterology. 2006;131(2):630–9.

    CAS  PubMed  Google Scholar 

  34. Nault JC, De Reynies A, Villanueva A, Calderaro J, Rebouissou S, Couchy G, Decaens T, et al. A hepatocellular carcinoma 5-gene score associated with survival of patients. Gastroenterology. 2013;145(1):176–87.

    CAS  PubMed  Google Scholar 

  35. Clavien PA, Lesurtel M, Bossuyt PMM, Gores GJ, Langer B, Perrier A. Recommendations for liver transplantation for hepatocellular carcinoma: an. Lancet Oncol. 2012;13(1):e11–22 LID. https://doi.org/10.1016/S470-2045(11)70175-9.

    Article  PubMed  Google Scholar 

  36. Yang XR, Xu Y, Yu B, Zhou J, Qiu S-J, Shi G-M, Zhang B-H, et al. High expression levels of putative hepatic stem/progenitor cell biomarkers. Gut. 2010;59(7):953–62.

    CAS  PubMed  Google Scholar 

  37. Pagano M, Benmaamar R. When protein destruction runs amok, malignancy is on the loose. Cancer Cell. 2003;4(4):251–6.

    CAS  PubMed  Google Scholar 

  38. Shirahashi H, Sakaida I, Terai S, Hironaka K, Kusano N, Okita K. Ubiquitin is a possible new predictive marker for the recurrence of human. Liver. 2002;22(5):413–8.

    CAS  PubMed  Google Scholar 

  39. Tu K, Yang W, Li C, Zheng X, Lu Z, Guo C, Yao Y, et al. Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest. Mol Cancer. 2014;13:110.

    PubMed  PubMed Central  Google Scholar 

  40. Kim JH, Sohn BH, Lee HS, Kim SB, Yoo JE, Park YY, et al. Genomic predictors for recurrence patterns of hepatocellular carcinoma: model derivation and validation. PLoS Med. 2014;11(12):e1001770. https://doi.org/10.1371/journal.pmed.1001770.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Kim SM, Leem SH, Chu IS, Park YY, Kim SC, Kim SB, et al. Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology. 2012;55(5):1443–52. https://doi.org/10.1002/hep.24813.

    Article  PubMed  Google Scholar 

  42. Lee JS, Chu IS, Mikaelyan A, Calvisi DF, Heo J, Reddy JK, et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet. 2004;36(12):1306–11. https://doi.org/10.1038/ng1481.

    Article  CAS  PubMed  Google Scholar 

  43. Roskams TA, Libbrecht L, Desmet VJ, Desmet VJ. Progenitor cells in diseased human liver. Semin Liver Dis. 2003;23(4):385–96.

    CAS  PubMed  Google Scholar 

  44. Schmelzer E, Wauthier E, Reid LM, Reid LM. The phenotypes of pluripotent human hepatic progenitors. Stem Cells. 2006;24(8):1852–8.

    CAS  PubMed  Google Scholar 

  45. Schmelzer E, Zhang L, Bruce A, Wauthier E, Ludlow J, Yao H, Moss N, et al. Human hepatic stem cells from fetal and postnatal donors. J Exp Med. 2007;204(8):1973–87.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, Budhu A, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of. Cancer Res. 2008;68(5):1451–61.

    CAS  PubMed  Google Scholar 

  47. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 2009;136(3):1012–24. https://doi.org/10.1053/j.gastro.2008.12.004.

    Article  CAS  PubMed  Google Scholar 

  48. Boyault S, Rickman DS, de Reynies A, Balabaud C, Rebouissou S, Jeannot E, Herault A, et al. Transcriptome classification of HCC is related to gene alterations and to new. Hepatology. 2007;45(1):42–52.

    CAS  PubMed  Google Scholar 

  49. Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, LeBlanc AC, et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res. 2008;68(16):6779–88.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Patil MA, Gutgemann I, Zhang J, Ho C, Cheung ST, Ginzinger D, Li R, et al. Array-based comparative genomic hybridization reveals recurrent chromosomal. Carcinogenesis. 2005;26(12):2050–7.

    CAS  PubMed  Google Scholar 

  51. Okamoto H, Yasui K, Zhao C, Arii S, Inazawa J. PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated. Hepatology. 2003;38(5):1242–9.

    CAS  PubMed  Google Scholar 

  52. Woo HG, Lee JH, Yoon JH, Kim CY, Lee HS, Jang JJ, Yi N-J, et al. Identification of a cholangiocarcinoma-like gene expression trait in. Cancer Res. 2010;70(8):3034–41.

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA, et al. An embryonic stem cell-like gene expression signature in poorly differentiated. Nat Genet. 2008;40(5):499–507.

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009;69(18):7385–92. https://doi.org/10.1158/0008-5472.CAN-09-1089.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Coulouarn C, Factor VM, Thorgeirsson SS. Transforming growth factor-beta gene expression signature in mouse hepatocytes. Hepatology. 2008;47(6):2059–67.

    CAS  PubMed  Google Scholar 

  56. The Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell. 2017;169(7):1327–41. https://doi.org/10.1016/j.cell.2017.05.046.

    Article  CAS  PubMed Central  Google Scholar 

  57. Shen R, Olshen AB, Ladanyi M. Integrative clustering of multiple genomic data types using a joint latent. Bioinformatics. 2009;25(22):2906–12.

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Desert R, Rohart F, Canal F, Sicard MA-O, Desille M, Renaud S, et al. Human hepatocellular carcinomas with a periportal phenotype have the lowest. Hepatology. 2017;66(5):1502–18.

    CAS  PubMed  Google Scholar 

  59. Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, Morabito A, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected. Gastroenterology. 2004;126(4):1005–14.

    PubMed  Google Scholar 

  60. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, et al. Risk factors contributing to early and late phase intrahepatic recurrence of. J Hepatol. 2003;38(2):200–7.

    PubMed  Google Scholar 

  61. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence. Cancer. 2000;89(3):500–7.

    CAS  PubMed  Google Scholar 

  62. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008;359(19):1995–2004.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6. Science. 2007;317(5834):121–4.

    CAS  PubMed  Google Scholar 

  64. Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, Andersson K, Chung RT, et al. Prognostic gene expression signature for patients with hepatitis C-related. Gastroenterology. 2013;144(5):1024–30.

    CAS  PubMed  Google Scholar 

  65. King LY, Canasto-Chibuque C, Johnson KB, Yip S, Chen X, Kojima K, et al. A genomic and clinical prognostic index for hepatitis C-related early-stage. Gut. 2015;64(8):1296–302.

    CAS  PubMed  Google Scholar 

  66. Kim JH, Sohn BH, Lee HS, Kim SB, Yoo JE, Park YY, et al. Genomic predictors for recurrence patterns of hepatocellular carcinoma: model. PLoS Med. 2014;11(12):e1001770.

    PubMed  PubMed Central  Google Scholar 

  67. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating. Nat Rev Drug Discov. 2006;5(10):835–44.

    CAS  PubMed  Google Scholar 

  68. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90. https://doi.org/10.1056/NEJMoa0708857.

    Article  CAS  PubMed  Google Scholar 

  69. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with. Lancet Oncol. 2009;10(1):25–34.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Sung Hwan Lee, Sun Young Yim, Jae-Jun Shim & Ju-Seog Lee

Authors
  1. Sung Hwan Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sun Young Yim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jae-Jun Shim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ju-Seog Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ju-Seog Lee .

Editor information

Editors and Affiliations

  1. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA

    Yujin Hoshida

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lee, S.H., Yim, S.Y., Shim, JJ., Lee, JS. (2019). Molecular Subtypes and Genomic Signatures of Hepatocellular Carcinoma for Prognostication and Therapeutic Decision-Making. In: Hoshida, Y. (eds) Hepatocellular Carcinoma. Molecular and Translational Medicine. Humana, Cham. https://doi.org/10.1007/978-3-030-21540-8_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-21540-8_6

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-21539-2

  • Online ISBN: 978-3-030-21540-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation